Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study
Authors
Krebs, Matthew GSpira, A. I.
Cho, B. C.
Besse, B.
Goldman, J. W.
Janne, P. A.
Ma, Z. Y.
Mansfield, A. S.
Minchom, A. R.
Ou, S. H. I.
Salgia, R.
Wang, Z. J.
Perez, C. L.
Gao, G.
Curtin, J. C.
Roshak, A.
Schnepp, R. W.
Thayu, M.
Knoblauch, R.
Lee, C. K.
Affiliation
The University of Manchester and The Christie NHS Foundation Trust, ManchesterIssue Date
2022
Metadata
Show full item recordCitation
Krebs M, Spira AI, Cho BC, Besse B, Goldman JW, Janne PA, et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302199.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.9008Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.9008Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.9008